Robotic prostatectomy (RARP) is a surgery for treatment localized prostate cancer. Bilateral pelvic lymph node dissection (BPLND) will also be performed if there is an estimated risk of occult nodal metastases exceeding 5%. BPLND in general is a well-tolerated procedure. Lymphatic leak is one of the possible complications after lymph node dissection (BPLND). Lymphocele is a collection of lymphatic fluid after operation. Hemopatch is a material used during operation that may prevent lymphorrhoea. This is a randomizedcontrolled trial that aims at investigating the application of Hemopatch to raw lymphatic tissue in preventing lymphorrhoea. Patients would be divided into 2 groups: with or without the use of Hemopatch during operation. They will be followed up on day 30 to monitor the course of recovery and any complications.
Conditions: Prostate Cancer
Eligibility Criteria
Inclusion Criteria
- Age 18 years and above
- Able to give informed consent
- Suitable for minimally-invasive surgery
Exclusion Criteria
- Known allergy or hypersensitivity to any component of Hemopatch®
- Known hypersensitivity to bovine proteins or brilliant blue
- Patients with prior pelvic radiotherapy
- Patients with non-correctable coagulopathy
- Patients who are on anticoagulants
- Contraindication to general anaesthesia
- Previous transurethral resection of the prostate or prostatic surgery
- Untreated active infection
Eligibility criteria are kept as the original English records from ClinicalTrials.gov; actual eligibility is determined by the research team's formal assessment and the informed consent form. Source: ClinicalTrials.gov, updated automatically every two weeks. Last synced: 2026年11月5日.